Hong Kong Media Stock News

Nayuki Holdings (SEHK:2150) has posted its FY 2025 first half numbers with revenue of C¥2,180.3 million and a basic EPS loss of C¥0.07 per share, alongside a net income loss of C¥117.1 million. The company has seen revenue shift from C¥2,544.4 million in the first half of 2024 to C¥2,180.3 million in the first half of 2025, while EPS moved from a loss of C¥0.25 to a loss of C¥0.07 over the same periods. This sets up a results season that keeps attention firmly on how efficiently each yuan of...

Unisound AI Technology (SEHK:9678) has reported its FY 2025 first half with revenue of C¥405.0 million and a loss per share of C¥4.28, alongside a net loss excluding extra items of C¥297.1 million, setting a clear focus on how quickly margins can improve from here. The company has seen first half revenue move from C¥337.0 million and EPS of C¥3.68 loss in FY 2024 to C¥405.0 million and EPS of C¥4.28 loss in FY 2025, while trailing twelve month revenue reached about C¥1.2 billion against a net...

Xin Point Holdings (SEHK:1571) has put fresh FY 2025 numbers on the table, with first half revenue of C¥1.56b and basic EPS of C¥0.24, set against trailing 12 month revenue of C¥3.15b and EPS of C¥0.53 that frame the latest run rate. The company has seen half year revenue move from C¥1.65b in 1H 2024 to C¥1.56b in 1H 2025, while basic EPS over those periods sits at C¥0.32 and C¥0.24 respectively. This gives investors a clear read on how top line and per share earnings are tracking into the...

Sino Biopharmaceutical (SEHK:1177) has just posted its FY 2025 results, with second half revenue of C¥14.3b and basic EPS of C¥0.06 loss, while the trailing twelve months show revenue of C¥31.8b and basic EPS of C¥0.13. Over recent reporting periods the company has seen revenue move from C¥13.0b in the second half of FY 2024 to C¥17.6b in the first half of FY 2025, alongside EPS shifting from C¥0.03 to C¥0.19 before the latest half year loss. This creates a mixed picture that puts the focus...

Meituan (SEHK:3690) has just wrapped up FY 2025 with fourth quarter revenue of about C¥90.97b and a net loss of roughly C¥15.14b, while the latest trailing twelve month figures show revenue of around C¥364.85b and a net loss of about C¥23.36b, translating to a TTM EPS of C¥3.84. Over recent periods the company has seen quarterly revenue move between roughly C¥86.56b and C¥95.49b, with net income ranging from a profit of about C¥10.06b in Q1 2025 to losses of C¥18.63b in Q3 2025. As a result,...

Shangri-La Asia FY 2025 earnings: modest top line, softer EPS sets the tone Shangri-La Asia (SEHK:69) has reported FY 2025 first half revenue of US$1,056.1 million and basic EPS of US$0.016, setting a more subdued headline than recent periods. The company has seen revenue move from US$1,049.1 million in 1H FY 2024 to US$1,136.2 million in 2H FY 2024 and US$1,056.1 million in 1H FY 2025, while basic EPS has shifted from US$0.0266 to US$0.0188 and then US$0.016 over the same halves, with...

Lonking Holdings (SEHK:3339) has reported FY 2025 first half revenue of C¥5.6b and basic EPS of C¥0.15, with the trailing twelve month numbers sitting at C¥11.2b in revenue and C¥0.30 in EPS, underscoring a clear reset from the prior year. Over recent periods the company has seen revenue move from C¥5.36b in 1H 2024 to C¥4.85b in 2H 2024 and then to C¥5.60b in 1H 2025. EPS has shifted from C¥0.11 to C¥0.13 and then to C¥0.15 over the same half yearly stretch, framing a profitability profile...

Founder Holdings (SEHK:418) has just reported its FY 2025 first half results, with revenue of HK$344.0 million and a basic EPS loss of HK$0.013 per share, while trailing twelve month figures show HK$907.2 million of revenue and basic EPS of HK$0.026. Over recent periods, the company has seen revenue move from HK$385.1 million in FY 2024 first half to HK$539.8 million in FY 2024 second half, and net income shift from a loss of HK$4.4 million to a profit of HK$52.3 million. This sets up the...

CStone Pharmaceuticals (SEHK:2616) has just posted its FY 2025 first half numbers, with revenue of C¥49.5 million and basic EPS showing a loss of C¥0.21, while trailing 12 month figures sit at C¥269.6 million of revenue and a loss of C¥0.31 in basic EPS. Over recent periods the company has seen revenue move from C¥254.2 million in the first half of 2024 to C¥153.0 million in the second half of 2024 and then to C¥49.5 million in the first half of 2025, with EPS shifting from a profit of C¥0.01...

Wing On Company International (SEHK:289) has reported its FY 2025 first half results with revenue of HK$416.2 million and a basic EPS loss of HK$0.52, while trailing twelve month figures show revenue of HK$1.4 billion and a basic EPS loss of HK$1.14. Over recent periods the company has seen revenue move from HK$480.0 million in 1H FY 2024 to HK$460.7 million in 2H FY 2024 and HK$416.2 million in 1H FY 2025, alongside EPS losses of HK$0.83, HK$2.34 and HK$0.52 respectively. This sets a clear...

BAIC Motor (SEHK:1958) has wrapped up FY 2025 with fourth quarter revenue of C¥43.2b and net income of C¥71.4m, while trailing twelve month EPS sits at C¥0.02 on revenue of C¥164.0b and net income of C¥122.7m. Over recent periods, the company has seen quarterly revenue move from C¥48.5b in Q4 2024 to C¥43.2b in Q4 2025, with EPS ranging between a loss of C¥0.27 per share in Q4 2024 and a modest profit of C¥0.02 per share on a trailing basis. With net margin at just 0.07% over the last year,...

Shenzhen Pagoda Industrial (Group) (SEHK:2411) reported FY 2025 first half revenue of C¥4.4b and a basic EPS loss of C¥0.23, keeping profitability firmly in the red despite a C¥342.1m net loss excluding extra items. Over the past three reported half year periods, revenue has moved from C¥5.6b in 1H 2024 to C¥4.7b in 2H 2024 and C¥4.4b in 1H 2025. Basic EPS shifted from a profit of C¥0.06 in 1H 2024 to losses of C¥0.32 in 2H 2024 and C¥0.23 in 1H 2025, highlighting earnings pressure that keeps...

Truly International Holdings (SEHK:732) has reported FY 2025 first half revenue of HK$8.1b and basic EPS of HK$0.0449, setting the tone for a year in which investors are watching how earnings quality holds up against thin margins. The company has seen revenue move from HK$8.6b in the first half of FY 2024 to HK$9.3b in the second half and then to HK$8.1b in the latest period. Basic EPS shifted from HK$0.0551 to HK$0.0405 and now HK$0.0449, giving a clear view of how the top line and EPS have...

Carote (SEHK:2549) has reported its FY 2025 first half results with revenue of ¥836.9 million and basic EPS of ¥0.19, alongside a prior year first half net income of ¥164.1 million and basic EPS of ¥0.41 that gives investors a clear year over year reference point. Over recent periods the company has seen trailing twelve month revenue move between ¥1.58 billion and ¥2.16 billion, with basic EPS ranging from ¥0.47 to ¥0.81, so the latest print lands in the middle of an already active earnings...

Rici Healthcare Holdings (SEHK:1526) has reported its FY 2025 first half with revenue of C¥1.1b and net income of C¥55.9m, translating to basic EPS of C¥0.04, while trailing twelve month EPS sits at C¥0.19 on revenue of about C¥2.8b and net income of C¥307.1m. Over recent halves, revenue has moved from C¥1.2b in 1H FY 2024 to C¥1.7b in 2H FY 2024 before settling at C¥1.1b in 1H FY 2025. Over the same periods, basic EPS shifted from C¥0.05 to C¥0.13 and then C¥0.04. With net profit margins...

WK Group (Holdings) (SEHK:2535) has reported its FY 2025 first half results with revenue of HK$165.5 million and basic EPS of HK$0.005416, setting a cautious tone against a backdrop of higher historic earnings. Over the prior two half year periods, the company has seen revenue move from HK$171.7 million in 1H 2024 to HK$226.8 million in 2H 2024, while basic EPS shifted from HK$0.008092 to HK$0.008377. Investors now face a set of FY 2025 numbers that sit alongside trailing 12 month net profit...

Build King Holdings (SEHK:240) has released its FY 2025 figures with first half revenue of HK$6.9b and basic EPS of HK$0.14, set against trailing twelve month revenue of HK$13.8b and EPS of HK$0.37 that reflect 4.3% earnings growth over the past year. Over the last three reported half year periods, revenue has moved from HK$6.5b in 1H 2024 to HK$7.9b in 2H 2024 and HK$6.9b in 1H 2025, while basic EPS has tracked from HK$0.12 to HK$0.23 and then HK$0.14, giving investors a clearer read on...

Wison Engineering Services (SEHK:2236) has released its FY 2025 results with first half revenue of C¥3.7b and basic EPS of C¥0.018, set against trailing 12 month EPS of C¥0.035 on revenue of C¥7.6b and net income of C¥142.4m. The company has seen revenue move from C¥5.6b with EPS of C¥0.034 in the 2024 second half on a trailing basis to C¥7.6b with EPS of C¥0.035 most recently. Five year annualized earnings growth of 33.2% and a 0.5% earnings uplift over the past year sit alongside a net...

Medlive Technology FY 2025 earnings snapshot Medlive Technology (SEHK:2192) has reported fresh numbers for FY 2025, with first half revenue of C¥312.0 million and basic EPS of C¥0.212. These figures help investors assess its current earnings power. The company’s revenue has moved from C¥243.4 million in the first half of 2024 to C¥315.0 million in the second half, and then to C¥312.0 million in the latest half. Over the same periods, basic EPS shifted from C¥0.202 to C¥0.230 and now C¥0.212...

Yuexiu Services Group (SEHK:6626) has reported its FY 2025 first half with revenue of C¥1.96b and basic EPS of C¥0.16, setting the tone for how the rest of the year could shape up for shareholders watching earnings quality and scale. The company has seen revenue hold around the C¥1.96b mark across the past two reported halves, with basic EPS moving from C¥0.18 in 1H 2024 to C¥0.05 in 2H 2024 before landing at C¥0.16 in 1H 2025. This gives a clear view of how profitability per share has...

ImmuneOnco Biopharmaceuticals (Shanghai) (SEHK:1541) has laid out its FY 2025 scorecard with first half revenue of C¥44.0 million and a basic EPS loss of C¥0.37, alongside net income loss excluding extra items of C¥152.6 million. The company has reported revenue of C¥0.7 million in 1H 2024, C¥78.8 million in 2H 2024 and C¥44.0 million in 1H 2025. Over the same periods, basic EPS losses were C¥0.44, C¥0.39 and C¥0.37 respectively, providing a basis to assess how effectively revenue is being...

Maxicity Holdings (SEHK:2295) has released its FY 2025 numbers with first half revenue of HK$131.4 million, basic EPS of HK$0.00924 and net income of HK$3.7 million, setting the tone for a year where profitability is squarely in focus. The company has seen revenue move from HK$84.8 million and EPS of HK$0.00418 in 1H 2024 to HK$120.99 million and HK$0.01769 in 2H 2024, before reaching HK$131.4 million and HK$0.00924 in 1H 2025. This gives investors a clear view of how the top line and EPS...

Fufeng Group (SEHK:546) has put fresh numbers on the table for FY 2025, with first half revenue of C¥13.96b and basic EPS of C¥0.71 setting the tone for its latest update. Over the last three reported halves, revenue has moved from C¥13.37b in 1H 2024 to C¥14.39b in 2H 2024 and C¥13.96b in 1H 2025, while basic EPS has shifted from C¥0.41 to C¥0.51 and then to C¥0.71, giving you a clear view of how the top and bottom lines are tracking through the cycle. Taken together with trailing twelve...

Jinxin Fertility Group (SEHK:1951) has opened FY 2025 with first half revenue of C¥1.29b and a basic EPS loss of C¥0.39, setting a cautious tone around profitability despite solid scale. Over the past year, revenue has moved from C¥1.44b in the first half of 2024 to C¥1.29b in the first half of 2025, while EPS shifted from C¥0.07 and C¥0.03 in the 2024 halves to a trailing 12 month loss of about C¥0.36. This points to compressed margins that put the focus firmly on how quickly management can...